Literature DB >> 24725494

When is prostate cancer really cancer?

David M Berman1, Jonathan I Epstein2.   

Abstract

Several investigators have challenged the idea that low-grade cancers are a cause for concern, suggesting that the term cancer should not be applied to these tumors. This article reviews the defining features of cancer, and the diagnostic and prognostic classification systems currently used for prostate cancer. Logical, morphologic, and molecular evidence is presented to show that low-grade prostate cancers are correctly classified as cancer. The authors suggest, however, that 6 out of 10 on an aggressiveness scale is inappropriate for indolent cancer, and that a proposed reinterpretation of Gleason grading categories is a more logical way to address overtreatment.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Gleason grade; Low-grade cancer; PSA screening; Prostate cancer

Mesh:

Substances:

Year:  2014        PMID: 24725494     DOI: 10.1016/j.ucl.2014.01.006

Source DB:  PubMed          Journal:  Urol Clin North Am        ISSN: 0094-0143            Impact factor:   2.241


  17 in total

1.  [The 2014 consensus conference of the ISUP on Gleason grading of prostatic carcinoma].

Authors:  G Kristiansen; L Egevad; M Amin; B Delahunt; J R Srigley; P A Humphrey; J I Epstein
Journal:  Pathologe       Date:  2016-02       Impact factor: 1.011

Review 2.  The potential of cell-free and exosomal microRNAs as biomarkers in liquid biopsy in patients with prostate cancer.

Authors:  Monyse de Nóbrega; Mariana Bisarro Dos Reis; Érica Romão Pereira; Marilesia Ferreira de Souza; Ilce Mara de Syllos Cólus
Journal:  J Cancer Res Clin Oncol       Date:  2022-08-04       Impact factor: 4.322

3.  Pericellular regulation of prostate cancer expressed kallikrein-related peptidases and matrix metalloproteinases by cell surface serine proteases.

Authors:  Janet C Reid; Admire Matsika; Claire M Davies; Yaowu He; Amy Broomfield; Nigel C Bennett; Viktor Magdolen; Bhuvana Srinivasan; Judith A Clements; John D Hooper
Journal:  Am J Cancer Res       Date:  2017-11-01       Impact factor: 6.166

4.  Future-proofing Gleason Grading: What to Call Gleason 6 Prostate Cancer?

Authors:  Stacy Loeb; Francesco Montorsi; James W Catto
Journal:  Eur Urol       Date:  2015-03-11       Impact factor: 20.096

5.  Evaluation of the 2015 Gleason Grade Groups in a Nationwide Population-based Cohort.

Authors:  Stacy Loeb; Yasin Folkvaljon; David Robinson; Ingela Franck Lissbrant; Lars Egevad; Pär Stattin
Journal:  Eur Urol       Date:  2015-12-17       Impact factor: 20.096

6.  A molecular signature of PCA3 and ERG exosomal RNA from non-DRE urine is predictive of initial prostate biopsy result.

Authors:  M J Donovan; M Noerholm; S Bentink; S Belzer; J Skog; V O'Neill; J S Cochran; G A Brown
Journal:  Prostate Cancer Prostatic Dis       Date:  2015-09-08       Impact factor: 5.554

7.  A Contemporary Prostate Cancer Grading System: A Validated Alternative to the Gleason Score.

Authors:  Jonathan I Epstein; Michael J Zelefsky; Daniel D Sjoberg; Joel B Nelson; Lars Egevad; Cristina Magi-Galluzzi; Andrew J Vickers; Anil V Parwani; Victor E Reuter; Samson W Fine; James A Eastham; Peter Wiklund; Misop Han; Chandana A Reddy; Jay P Ciezki; Tommy Nyberg; Eric A Klein
Journal:  Eur Urol       Date:  2015-07-10       Impact factor: 20.096

Review 8.  Should Gleason 6 be labeled as cancer?

Authors:  Ibrahim Kulac; Michael C Haffner; Srinivasan Yegnasubramanian; Jonathan I Epstein; Angelo M De Marzo
Journal:  Curr Opin Urol       Date:  2015-05       Impact factor: 2.309

9.  A panel of selected serum protein biomarkers for the detection of aggressive prostate cancer.

Authors:  Jin Song; Shiyong Ma; Lori J Sokoll; Rodrigo V Eguez; Naseruddin Höti; Hui Zhang; Phaedre Mohr; Renu Dua; Dattatraya Patil; Kristen Douglas May; Sierra Williams; Rebecca Arnold; Martin G Sanda; Daniel W Chan; Zhen Zhang
Journal:  Theranostics       Date:  2021-04-15       Impact factor: 11.556

10.  How Much Reliable Is the Current Belief on Grade Group 1 Prostate Cancer?

Authors:  Mun Su Chung; Yeong Jin Choi; Young Sub Lee; Byung Il Yoon; U-Syn Ha
Journal:  Pathol Oncol Res       Date:  2021-04-13       Impact factor: 3.201

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.